Register for free
Recent Quotes
My Watchlist
Indicators
Business Insurance Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Aldeyra Therapeutics, Inc. - Common Stock (NQ:ALDX)

2.300 +0.140 (+6.50%)
Streaming Delayed Price Updated: 2:08 PM EDT, May 19, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Aldeyra Therapeutics, Inc. - Common Stock

< Previous 1 2
...
5 6 7 8 9 10 11 12 Next >
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Aldeyra Therapeutics, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - ALDX
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
Exposures Financial Legal Product Safety
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Aldeyra Therapeutics, Inc. (ALDX) on Behalf of Investors
From Glancy Prongay & Murray LLP
Via Business Wire
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Aldeyra Therapeutics, Inc. (ALDX) on Behalf of Investors
From Law Offices of Howard G. Smith
Via Business Wire
Analyst Ratings for Aldeyra Therapeutics
Via Benzinga
Recap: Aldeyra Therapeutics Q1 Earnings
Via Benzinga
The Law Offices of Frank R. Cruz Announces Investigation of Aldeyra Therapeutics, Inc. (ALDX) on Behalf of Investors
From The Law Offices of Frank R. Cruz
Via Business Wire
EQUITY ALERT: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Aldeyra Therapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action – ALDX
From Rosen Law Firm
Via Business Wire
Shareholder Alert: Robbins LLP Informs Shareholders of Class Action Filed Against Aldeyra Therapeutics, Inc. (ALDX)
From Robbins LLP
Via Business Wire
Aldeyra Therapeutics to Participate in SVB Securities Therapeutics Forum
From Aldeyra Therapeutics, Inc.
Via Business Wire
Aldeyra Therapeutics Announces Improvement from Baseline in Retinal Function in Phase 2 Clinical Trial of ADX‑2191 in Patients with Retinitis Pigmentosa
From Aldeyra Therapeutics, Inc.
Via Business Wire
Aldeyra Therapeutics Schedules Conference Call and Webcast to Announce Top-Line Results from the Phase 2 Clinical Trial of ADX-2191 in Patients with Retinitis Pigmentosa
From Aldeyra Therapeutics, Inc.
Via Business Wire
Aldeyra Therapeutics' Chronic Cough Potential Shows Significant Reduction In Cough Frequency Versus Placebo
Aldeyra Therapeutics Inc (NASDAQ: ALDX) announced top-line results from the Phase 2 clinical trial of ADX‑629, an investigational new drug administered orally to 
Via Benzinga
Aldeyra Therapeutics Announces Statistically Significant Reduction in Cough Frequency in Phase 2 Clinical Trial of ADX‑629 in Patients With Chronic Cough
From Aldeyra Therapeutics, Inc.
Via Business Wire
Aldeyra Therapeutics Schedules Conference Call and Webcast to Announce Top-Line Results from the Phase 2 Clinical Trial of ADX‑629 in Patients with Chronic Cough
From Aldeyra Therapeutics, Inc.
Via Business Wire
Aldeyra Therapeutics to Join the Russell 2000® and Russell 3000® Indexes
From Aldeyra Therapeutics
Via Business Wire
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
Why Are Aldeyra Therapeutics Shares Plummeting Today
Aldeyra Therapeutics Inc (NASDAQ: ALDX) has received a Complete Response Letter from the FDA for the 505(b)(2) New Drug Application (NDA) of ADX-2191 (methotrexate for injection) for  
Via Benzinga
Aldeyra Therapeutics Provides Regulatory Update on ADX-2191
From Aldeyra Therapeutics
Via Business Wire
Why John Wiley & Sons Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Gainers SCWorx Corp. (NASDAQ: WORX) shares jumped 281% to $0.8396. 
Via Benzinga
Why Aldeyra Therapeutics Stock Is Trading Higher Today
Aldeyra Therapeutics Inc (NASDAQ: ALDX) reported topline results from the Phase 3 INVIGORATE-2 trial of 0.25% reproxalap ophthalmic solution, an investigational new drug, in  
Via Benzinga
Domino's Pizza, Patterson-UTI Energy, JinkoSolar And Other Big Stocks Moving Higher On Thursday
U.S. stocks traded higher, with the Dow Jones gaining around 180 points on Thursday. Here are some big stocks recording gains in today’s session. Nikola Corporation (NASDAQ: NKLA) jumped 19.9% to... 
Via Benzinga
Aldeyra Therapeutics Schedules Conference Call and Webcast to Announce Top-Line Results from the Phase 3 INVIGORATE‑2 Trial in Allergic Conjunctivitis
From Aldeyra Therapeutics, Inc.
Via Business Wire
Aldeyra Therapeutics to Participate in Fireside Chat at the Jefferies Global Healthcare Conference
From Aldeyra Therapeutics, Inc.
Via Business Wire
Aldeyra Therapeutics Reports First-Quarter 2023 Financial Results and Recent Corporate Highlights
From Aldeyra Therapeutics, Inc.
Via Business Wire
R&D Activities for Treating Dry Eye Syndrome Resulting in Promising Pipeline of Treatments
EQNX::TICKER_START (NASDAQ:OKYO),(NYSE:NVS),(NASDAQ:ALDX),(NASDAQ:OCUL),(NASDAQ:EYPT) EQNX::TICKER_END 
Via FinancialNewsMedia
Exposures COVID-19
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
The Week In Charts: 0DTE Options - Too Good To Be True?
Zero-days; how Core Methodology can be used in Crypto, with current Crypto and stock market conditions; favorite stock picks. 
Via Talk Markets
Short Volatility Alert: Aldeyra Therapeutics
On Thursday, shares of Aldeyra Therapeutics (NASDAQ: ALDX) experienced volatile short activity. After the activity, the stock price went down -0.22% to $9.05. The overall sentiment for ALDX has been... 
Via Benzinga
OKYO Pharma Management Takes Company Stock In Private Placement Instead Of Deferred Pay
Drug development can be notoriously slow, and it can take some companies 10 years or more to pass through all the trials and tests required by the Food and Drug Administration (FDA). 
Via Benzinga
Aldeyra Therapeutics Completes Enrollment in Phase 3 INVIGORATE-2 Clinical Trial in Allergic Conjunctivitis
From Aldeyra Therapeutics, Inc.
Via Business Wire
< Previous 1 2
...
5 6 7 8 9 10 11 12 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.

Never miss important news. Subscribe to our newsletter.
Register for free

Information

Copyright 2024. BUSINESS INSURANCE HOLDINGS